Complete Up To Date Information about Vetalog Parenteral Veterinary.
NADA Number: 012-198 | |
| Proprietary Name |
Vetalog Parenteral Veterinary |
|---|---|
| Sponsor |
Fort Dodge Animal Health, Division of Wyeth Holdings Corp. |
| Sponsor Address |
P. O. Box 1339 Fort Dodge, IA 50501 USA |
| Ingredients |
Triamcinolone Acetonide |
| Species |
Horse, not for meat production Cat, restricted during pregnancy Dog, restricted during pregnancy |
| Routes of Administration |
Intra-articular Intrasynovial Intramuscular Intralesional (cats) Subcutaneous Intralesional (dogs) |
| Dose Form |
Liquid (suspension) |
| Drug Form |
Liquid (suspension) |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
522.2483 Sterile triamcinolone acetonide suspension. Specifications: Each milliliter of suspension contains 2 or 6 milligrams triamcinolone acetonide. Conditions of use: Dogs Amount: Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams. Indications: Treatment of inflammation and related disorders in dogs; and management and treatment of acute arthritis and allergic and dermatologic disorders in dogs. Limitations: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Cats Amount: Intramuscular or subcutaneous: Single injection of 0.05 to 0.1 milligram per pound of body weight in inflammatory, arthritic or allergic disorders. Single injection of 0.1 milligram per pound of body weight in dermatologic disorders. If symptoms recur the dose may be repeated, or oral corticosteroid therapy may be instituted. Intralesional: 1.2 to 1.8 milligrams, divided in several injections, spaced around the lesion at 0.5 to 2.5 centimeters apart depending on the size. At any one site the dose injected should not exceed 0.6 milligrams and should be well into the cutis to prevent rupture of the epidermis. When treating animals with multiple lesions, do not exceed a total dose of 6 milligrams. Intra-articular and intrasynovial: Single injection of 1 to 3 milligram dose, dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage exceed 3 milligrams. Indications: Treatment of inflammation and related disorders in cats; and management and treatment of acute arthritis and allergic and dermatologic disorders in cats. Limitations: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Horses Amount: Intramuscular or subcutaneous: Single injection of 0.01 to 0.02 milligrams per pound of body weight. Usual dose, 12 to 20 milligrams. Intra-articular and intrasynovial: Single injection of 6 to 18 milligram dose dependent on size of joint and severity of symptoms. After 3 or 4 days, repeat dosage if indicated. If initial results are inadequate or too transient, dosage may be increased not to exceed 18 milligrams. Indications: Treatment of inflammation and related disorders in horses. Limitations: Do not use in viral infections. With bacterial infections appropriate antibacterial therapy should be used. Do not use in animals with tuberculosis, chronic nephritis or cushingoid syndrome, except for emergency therapy. Not for use in horses intended for food. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Do not use in the treatment of laminitis. Intra-articular injection in equine leg injuries may produce osseous metaplasia. Federal law restricts this drug to use by or on the order of a licensed veterinarian. NAS/NRC status: These conditions are NAS/NRC reviewed and are deemed effective. Applications for these uses need not include the effectiveness data specified by 514.111 of this chapter, but may require bioequivalency and safety information. |